Home / Contract Awards / HHS Taps Profectus BioSciences for Ebola, Marburg Vaccine R&D

HHS Taps Profectus BioSciences for Ebola, Marburg Vaccine R&D

BiomedicalNIHThe Department of Health and Human Services has awarded Profectus BioSciences an $8.6 million contract to further develop and test a vaccine designed to treat infections caused by Ebola and Marburg viruses.

HHS said Tuesday the cost-plus-fixed-fee contract covers research and development of Profectus’ Ebola and Marburg filovirus vaccine rVSVN4CT1.

Profectus presented data from animal studies on the injectable drug at the Filovirus Medical Countermeasures Meeting hosted by the National Institutes of Health in Maryland last year.

The biotechnology firm said its rVSV‐based vaccines gave 100 percent protection to monkeys from Ebola and Marburg during government-backed research.

According to the company, the rVSV vaccine delivery vector is designed to trigger antibody responses in the surface glycoproteins of several infectious diseases as well as biothreat agents.

Check Also

Avon Rubber Books $333M Body Armor Supply Contract With DLA

The Defense Logistics Agency has selected U.K.-based protective equipment supplier Avon Rubber for a potential  $333M framework contract to provide body armor plates from its recently acquired business, Ceradyne.

Aerospace Defense Firms Launch Measures to Avoid COVID-19 Spread; Ellen Lord Quoted

Boeing (NYSE: BA), Textron’s (NYSE: TXT) Bell subsidiary and other aerospace defense manufacturers have increased cleaning efforts and implemented telework capabilities, social distancing and other measures to prevent the spread of the coronavirus and maintain operations, FlightGlobal reported Friday. Other companies that have initiated similar efforts are Lockheed Martin (NYSE: LMT), Northrop Grumman (NYSE: NOC), Sikorsky and AeroVironment.